{"news_desk": "Business", "print_page": "2", "section_name": "Business Day", "subsection_name": "DealBook", "document_type": "article", "multimedia": [], "abstract": "Tekmira Pharmaceuticals Corporation agrees to buy OnCore Biopharma for about $750 million, to develop hepatitis B virus drugs.", "type_of_material": "Brief", "word_count": "126", "lead_paragraph": "The implied market value of the merged company is about $750 million.", "pub_date": "2015-01-13T00:00:00Z", "_id": "54b4624d38f0d8623a353f6c", "byline": {"contributor": "", "original": "By REUTERS", "person": [], "organization": "REUTERS"}, "source": "The New York Times", "snippet": "The implied market value of the merged company is about $750 million.", "web_url": "http://www.nytimes.com/2015/01/13/business/dealbook/tekmira-to-buy-oncore-and-develop-hepatitis-b-drugs.html", "slideshow_credits": null, "blog": [], "keywords": [{"rank": "1", "is_major": "Y", "value": "Tekmira Pharmaceuticals Corporation", "name": "organizations"}, {"rank": "2", "is_major": "Y", "value": "OnCore Biopharma Inc", "name": "organizations"}, {"rank": "3", "is_major": "N", "value": "Mergers, Acquisitions and Divestitures", "name": "subject"}, {"rank": "4", "is_major": "N", "value": "Hepatitis", "name": "subject"}, {"rank": "5", "is_major": "N", "value": "Drugs (Pharmaceuticals)", "name": "subject"}], "headline": {"main": "Tekmira to Buy Oncore and Develop Hepatitis B Drugs", "content_kicker": "Business Briefing", "print_headline": "Tekmira to Buy OnCore and Develop Hepatitis B Drugs", "kicker": "Business Briefing"}}